Douglas A Hanson

US Patent:

8198251, Jun 12, 2012

Filed:

Aug 12, 2008

Appl. No.:

12/190402

Inventors:

Jorg Vollmer - Dusseldorf, DE
Eugen Uhlmann - Glashuetten, DE
Arthur M. Krieg - Wellesley MA, US
Douglas C. Hanson - Niantic CT, US
Ulrike Samulowitz - Langenfeld, DE

Assignee:

Coley Pharmaceutical GmbH - Düsseldorf
Coley Pharmaceutical Group, Inc. - Wellesley MA
Pfizer Inc - New York NY

International Classification:

A61K 48/00

US Classification:

514 44R

Abstract:

Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5′ TCGTCGTTTTCGGCGCGCGCCGT 3′ (SEQ ID NO: 1), in which each C is unmethylated and 3′ refers to the 3′ end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-γ. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.

US Patent:

20120219571, Aug 30, 2012

Filed:

May 14, 2012

Appl. No.:

13/470729

Inventors:

JORG VOLLMER - DUSSELDORF, DE
EUGEN UHLMANN - GLASHUETTEN, DE
ARTHUR M. KRIEG - WELLESLEY MA, US
DOUGLAS C. HANSON - NIANTIC CT, US
ULRIKE SAMULOWITZ - LANGENFELD, DE

Assignee:

COLEY PHARMACEUTICAL GMBH - Dusseldorf
PFIZER INC - New York NY
COLEY PHARMACEUTICAL GROUP, INC. - Wellesley MA

International Classification:

A61K 31/7088
A61P 37/04
A61P 31/00
A61P 37/08
C07H 21/04
A61P 35/00

US Classification:

4241841, 536 231

Abstract:

Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5′ TCGTCGTTTTCGGCGCGCGCCGT 3′ (SEQ ID NO: 1), in which each C is unmethylated and 3′ refers to the 3′ end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-γ. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.

US Patent:

D2918994, Sep 15, 1987

Filed:

Dec 18, 1984

Appl. No.:

6/683207

Inventors:

Douglas M. Hanson - Nashua NH
Jeff D. Hanson - Nashua NH
Brian E. Hanson - Nashua NH

Assignee:

JMBL Corporation - Nashua NH

US Classification:

D21 23